3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
169
Precursor Cell Lymphoblastic Leukemia-Lymphoma
33
Recurrence
28
Leukemia
24
Vomiting
23
Neoplasms, Plasma Cell
20
Lymphoma
18
Neoplasms
16
Nausea
13
Burkitt Lymphoma
11
Prostatic Neoplasms
8
Immunoglobulin Light-chain Amyloidosis
7
Carcinoma, Non-Small-Cell Lung
6
Lymphoma, Follicular
5
Lung Neoplasms
5
Hodgkin Disease
5
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Lymphoma, Non-Hodgkin
4
Leukemia, Biphenotypic, Acute
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Small Cell Lung Carcinoma
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Paraproteinemias
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large B-Cell, Diffuse
3
Fallopian Tube Neoplasms
3
Interventions
Gemcitabine
2
liposomal doxorubicin
1
fosaprepitant
1
argatroban
1
Palonosetron
1
Paclitaxel
1
Heparin, Low-Molecular-Weight
1
Drug Therapy
1
Diet
1
Dexamethasone
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Genital Neoplasms, Female
×
Dexamethasone
×
Clear all
NCT01074697
2015-04-24
GAND-emesis
Odense University Hospital
Phase 3
Completed
246 enrolled